Vertex Inc. A

Vertex shares dropped about 13% after disappointing cloud growth, although the overall quarter was slightly above consensus. Management cut its 2026 cloud-growth forecast from 25% to 18%, citing delayed cloud migrations. Several analysts then lowered their price targets (examples: DA Davidson 15→12 USD, Stephens 20→18 USD, Baird 19→17 USD). Vertex also reported three executive appointments, including a new chief product and technology officer. » More on de.investing.com

Vertex names Chatelle Lynch as Chief People Officer, Carlos Mercuriali as Senior Vice President and regional manager for Europe, and Bala Chandran as Chief Product and Technology Officer. The appointments are intended to bolster talent management, regional expansion in Europe, and technological innovation for the company’s SaaS- and AI-first strategy. Vertex emphasizes that the new leaders will support further global growth and the company’s adaptation to increasing e-invoicing and real-time compliance requirements. » More on finanzen.net

Vertex agreed to acquire Crinetics for $85 per share in cash, implying an equity value of about $10 billion (roughly $8.8 billion net of acquired cash), with the deal expected to close in Q3 2026 after unanimous board approvals. UBS initiated coverage of Crinetics with a Buy rating and a $55 price target, highlighting a 44% stock decline since January and multiple pipeline catalysts. Crinetics' endocrine-focused assets, including PALSONIFY and Phase 3 atremelnant, underpin Vertex's expectation of more than $5 billion in potential combined peak annual revenue. » More on finance.yahoo.com